Skip to main content

Turning Ophthalmology AI Research into a Scalable Clinical Platform

Blüm Health is collaborating with AI Sight in transforming University of Liverpool research into a regulated digital health platform designed to help screening teams detect diabetic retinopathy earlier, prioritise clinical review and manage growing demand more efficiently.

AI Sight: Translating ophthalmology AI research into a regulated digital health platform

University spin-out | AI in ophthalmology | Diabetic retinopathy screening | Software as a Medical Device | Commercialisation support

Blüm Health is collaborating with AI Sight, a University of Liverpool spin-out commercialising artificial intelligence research in diabetic eye screening.

AI Sight was founded to bring a next-generation AI system from academic research into real-world use, supporting earlier identification of diabetic retinopathy and helping clinical teams manage the growing demand for eye-screening services. The technology applies machine learning to retinal images, combining human clinical expertise with machine judgement to interpret and rank images across disease severity and treatment intervention points.

Diabetic retinopathy is one of the world’s leading causes of preventable sight loss. Screening is essential because it can identify disease early enough for sight-saving interventions, but screening programmes rely on significant clinical grading capacity. This creates operational pressure for services and can introduce variability in assessment, particularly as demand continues to rise.

AI Sight is designed as an assisted grading tool that supports, rather than replaces, clinical expertise. The platform analyses digital colour fundus images and classifies diabetic retinopathy risk to help screening teams prioritise review, escalate higher-risk or uncertain cases, and manage lower-risk images more efficiently within existing clinical workflows.

Blüm Health worked with AI Sight as an end-to-end healthtech delivery partner, supporting the translation of complex academic research into a commercially viable, regulated digital health product. This included AI consultancy, software development, cloud architecture, product design and medical device regulatory compliance support.

The work involved building the technical foundations for a scalable digital health platform, including secure cloud-hosted infrastructure, image processing workflows, API connectivity, user-facing software components, administrative tools and support for clinical workflow integration.

Blüm Health also supported the development of the regulatory and quality foundations required for Software as a Medical Device, including quality management, software lifecycle processes, risk management, technical documentation, usability engineering, verification and validation planning, clinical evaluation support and DTAC compliance preparation.

Relevant capabilities

  • AI-enabled healthcare product development

  • Software as a Medical Device development

  • Medical device regulatory compliance

  • Digital health commercialisation

  • University spin-out support

  • Ophthalmology and retinal imaging technology

  • Machine learning deployment in healthcare

  • Cloud architecture and secure infrastructure

  • Clinical workflow integration

  • UX and product design for healthcare users

  • Quality management and technical documentation

  • Risk management and software lifecycle processes

  • DTAC and NHS readiness support

  • End-to-end healthtech delivery

You can find out more about the AI Sight project here